Capricor Therapeutics Inc
Change company Symbol lookup
Select an option...
CAPR Capricor Therapeutics Inc
DLNG-A Dynagas LNG Partners LP
EEX Emerald Holding Inc
APEN Apollo Endosurgery Inc
TUP Tupperware Brands Corp
BYZN Byzen Digital Inc
XOM Exxon Mobil Corp
EPD Enterprise Products Partners LP
STLB Sterling Business Solutions Inc
CITY Avalon Correctional Services Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.

Price
Delayed
$5.50
Day's Change
0.11 (2.04%)
Bid
--
Ask
--
B/A Size
--
Day's High
5.74
Day's Low
5.40
Volume
(Light)

Today's volume of 561,043 shares is on pace to be much lighter than CAPR's 10-day average volume of 2,770,922 shares.

561,043
Latest Earnings Beat Consensus (Q1 ending 03/2020)Next Earnings Announcement
Q1
Announced May 14, 2020
-$0.30Q1 Consensus
of 2 analysts
-$0.33Difference from
consensus
10.00%
Q2 Earnings
will announce
(Unconfirmed) August 4, 2020

Quarterly Earnings History and Estimates

Show high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.

Display:

UpdateCancel

CAPR's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.